Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Dec 11, 2022 9:00am EST
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th Dec 07, 2022 4:05pm EST
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib Nov 14, 2022 7:30am EST
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022 Oct 18, 2022 4:01pm EDT
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D. Sep 13, 2022 7:30am EDT
